Please note that this product was withdrawn from the Community Register of designated orphan medicinal products in August 2016 on request of the sponsor.
On 8 November 2012, orphan designation (EU/3/12/1061) was granted by the European Commission to MedImmune Ltd, United Kingdom, for tralokinumab for the treatment of idiopathic pulmonary fibrosis.
|Disease / condition||
Treatment of idiopathic pulmonary fibrosis
|Date of first decision||
|EU designation number||
Review of designation
Sponsor's contact details
For contact details of patients’ organisations whose activities are targeted at rare diseases, see:
Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.
European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.